

**Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
05 Oct – 07 Oct 2020
Virtual Meeting
Draft agenda**

Monday, 05 October 2020

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
10:00	Closed SAGE meeting	Preparation of the sessions of the day. Other important discussion items.	1h
11:00	Break	Break	15 min
11:15	Opening Opening remarks by Zsuzsanna JAKAB, Deputy Director-General, WHO. Welcome – introduction of participants A. CRAVIOTO. Chair of SAGE.	Opening of the Plenary Meeting	10 min
11:25	Global Reports - Session 1 Report from the Director of IVB. K. O'BRIEN. WHO. 20 min. Discussion: 15 min. Update from Gavi. S. BERKLEY. GAVI. 10 min. Discussion: 10 min.	FOR INFORMATION	55 min
12:20	Break	Break	15 min.
12:35	Immunization in the context of the COVID-19 pandemic, including regional and country focus – Session 2 A. Impact of the COVID-19 pandemic on immunization activities Introduction to session. N. MACDONALD. SAGE Member. 5 min. Impact of COVID-19 on immunization programme implementation, 70 min. <ul style="list-style-type: none"> Regional situation reports and country highlights (8 min per region), 50 min. Update on global monitoring and activities to support resumption of services. D. CHANG BLANC. WHO. 20 min. Discussion of revised statement. N. MACDONALD. SAGE Member. 35 min.	FOR DISCUSSION AND DECISION To update SAGE on the programmatic impact of COVID-19 and request appraisal of a new version of ' <i>Guiding Principles for immunization activities during the COVID-19 pandemic</i> (26 March 2020)'.	1h 50 min
14:25	B. Briefs to review evidence for COVID-19 co-morbidity and benefit of vaccination in relation to Influenza and Pneumococcus <ul style="list-style-type: none"> Influenza. M. FRIEDE. WHO. 10 min. 	FOR INFORMATION	30 min

14 September 2020

	<ul style="list-style-type: none"> Pneumococcal disease. S. DESAI. WHO. 10 min. <p>Discussion. 10 min.</p>	
14:55	Break	BREAK 10 min
15.05	<p>COVID-19 vaccination – Session 3</p> <p>Introduction to session and values framework. H. NOHYNEK SAGE Member. 5 min.</p> <p>Burden of Disease and at-risk populations. TBD. 10 min.</p> <p>Vaccine platforms and their stage in development. H. NOHYNEK. SAGE Member. 10 min.</p> <p>Vaccine Impact modelling: preliminary results. N. GRASSLY & S. PALLAS. 30 min.</p> <p>Q&A 15 min.</p> <p>Prioritization and potential use case scenarios. R. FADEN. 30 min.</p> <p>Q&A 10 min.</p> <p>Safety appraisal and pharmacovigilance planning. S. OMER. GACVS. 10 min.</p>	<p>FOR DISCUSSION AND DECISION</p> <p>Discussion session under the assumption that no vaccine is registered by the time of the meeting.</p> <p>1h 30 min</p>
16:35	End of the day	

Tuesday, 06 October 2020

10:00	Closed SAGE meeting	Preparation of the sessions of the day. Recap of day 1. Other important discussion items.	1h
11:00	Break	Break	15 min
11:15	<p>Polio - Session 4</p> <p>Update from the Global Polio Eradication Initiative. M. ZAFFRAN. WHO. 10 min.</p> <p>Observations to global update from polio SAGE WG I Jani. SAGE Member. 5 min</p> <p>Questions: 5 min.</p> <p>Two-dose IPV routine immunization schedule</p> <ul style="list-style-type: none"> Immunogenicity data from trials with 2-dose IPV and fIPV O. MACH. WHO. 5 min Options for 2nd dose introduction A. Ramirez. WHO. 5 min <p>Suggested recommendations on two-dose IPV schedule from polio SAGE WG I Jani. SAGE Member. 5 min</p> <p>Questions: 5 min.</p> <p>Update on nOPV2 development</p> <ul style="list-style-type: none"> EUL process C. Rodriguez. WHO. 5 min Proposed 'type 2' vaccine use framework G. MACKLIN. WHO. 5 min 	<p>FOR DECISION</p> <p>SAGE will be informed on the current status of the polio eradication program in the context of COVID-19 and on nOPV2 development.</p> <p>SAGE is asked to review the evidence and make recommendations on:</p> <ul style="list-style-type: none"> Recommendation on 2nd IPV dose in routine immunization GPEI 'type 2' vaccine use framework Recommendation on use of IPV for poliovirus outbreak response 	1h 30 min

<p>Suggested recommendations on nOPV from polio SAGE WG. I Jani SAGE Member. 5 min Questions: 5 min.</p> <p>Remaining items to report from SAGE Polio Working Group including considerations for IPV use in poliovirus outbreak response. I Jani. SAGE Member. WHO. 10 min</p> <p>Discussion: 20 min.</p>			
12:45	Break	Break	30 min
13:15	Ebola vaccines - Session 5	FOR DECISION	1h 30 min
<p>Introduction to session and key questions. E. MOHSNI. SAGE Member. 5 min.</p> <p>Epidemiological update. TBC. 10 min.</p> <p>Review of safety, immunogenicity and efficacy of rVSV-ZEBOV GP in children 6 months to 17 years, pregnant women and breastfeeding women. TBC. 15 min.</p> <p>Review of evidence on duration of protection (preclinical and clinical data) of rVSV-ZEBOV-GP. TBC. 10 min.</p> <p>Review of the potential target populations for Ebola vaccines and vaccines availability and demand scenarios for preventive vaccination. TBC. 15 min.</p> <p>Conclusions and proposed recommendations by SAGE Working Group. 5 min.</p> <p>Discussion: 30 min.</p>		<p>Present SAGE with updated evidence on Ebola vaccines on the safety and efficacy in children 6 months to 17 years of age, pregnant women and breastfeeding women; on the duration of protection and the potential supply and demand scenarios and the vaccination strategies.</p> <p>SAGE is requested to address the following questions:</p> <p><i>Question 1: Potential recommendation for off-label use of rVSV ZEBOV GP.</i></p> <p>What does current evidence show on the immunogenicity and efficacy of rVSV-ZEBOV-GP for children 6 months to 17 years of age, pregnant women and breastfeeding women? And what are the limitations of the available evidence?</p> <p><i>Question 2: Potential recommendation on the preventive use of Ebola vaccines</i></p> <p>Is the current evidence on the duration of protection of rVSV-ZEBOV-GP sufficient to inform policy recommendations on the preventive use of this vaccine? And what are the limitations of the available evidence? Recommendations on the use of Ebola Ad26/MVA vaccine.</p> <p><i>Question 3: Potential recommendations on the strategies to ensure equitable and fair access to Ebola vaccines</i></p> <p>What are the potential demand scenarios and supply scenarios for various Ebola vaccines (short and mid-term outlook)? In light of the above conclusions/inputs, how should this Ebola vaccine allocation be prioritized with respect to impact and equity?</p>	
14:45	Break	Break	15 min.
15:00	Rotavirus vaccines - Session 6	FOR DECISION	1h
<p>Introduction to session, background, and key questions. K. NEUZIL. SAGE Member. 10 min.</p> <p>Systematic review of evidence on efficacy, effectiveness, and safety. N. HENSCHKE. Cochrane Response. 10 min.</p> <p>Overview of findings and proposals from the SAGE Ad-hoc Working Group. K. NEUZIL. SAGE Member. 10 min.</p> <p>Discussion: 30 min.</p>		<p>Present SAGE with updated evidence on efficacy, effectiveness and safety of rotavirus vaccines and on programmatic experience with using rotavirus vaccines.</p> <p>SAGE is requested to address the following questions:</p> <ul style="list-style-type: none"> • Does the evidence on the safety and efficacy for Rotavac and Rotasiil support a WHO recommendation for global use? • Can recommendations for for the 4 currently prequalified rotavirus vaccines (Rotarix, RotaTeq, Rotavac, and Rotasiil) be generic? • Can recommendations for upcoming similar vaccines be generic? If not, what 	

	<p>recommendations need to be specified by product?</p> <ul style="list-style-type: none"> • In the context of the disruption due to the COVID-19 pandemic or other immunization system disruptions, are there special considerations for rotavirus vaccination catch-up? If yes, what are they? • What are the clinical and programmatic research questions needed to generate data for future policy and program decisions?
16:00	End of the day

Wednesday, 07 October 2020

10:00	Closed SAGE meeting	Preparation of the sessions of the day. Recap of day 2. Other important discussion items.	1h
11:00	Break	Break	15 min
11:15	Measles Rubella Strategic Framework - Session 7	FOR DECISION	1h
	<p>Introduction to session and key questions. K. MULHOLLAND. SAGE Member. 5 min.</p> <p>Presentation of the Measles Rubella Strategic Framework. N. CROWCROFT. WHO. 15 min.</p> <p>Discussion: 40 min.</p>	SAGE is requested to appraise the Measles and Rubella Strategic Framework	
12:15	IA2030: Development of the IA2030 Monitoring, Evaluation, and Action and Ownership and Accountability Frameworks - Session 8	FOR DISCUSSION	1h
	<p>Overview of IA2030 ME&A Framework Development. E. MAST. US CDC. 20 min.</p> <p>Emerging IA2030 Ownership & Accountability mechanism options. A. LINDSTRAND. WHO. 10 min.</p> <p>Discussion: 30 min.</p>	<p>The session will centre on two key objectives:</p> <ol style="list-style-type: none"> 1. Share updates from the Immunization Agenda 2030 (IA2030) Monitoring & Evaluation Task Force and IA2030 Core Team of partners, including: <ul style="list-style-type: none"> • Proposed IA2030 Strategic Priority (SP) Objective indicators • Proposed Impact Goal (IG) indicators • Proposed options to set targets for IG and SP Objective indicators • Emerging design options for the Ownership & Accountability (O&A) mechanism 2. Receive guidance from SAGE on: <ul style="list-style-type: none"> • ME&A Framework architecture and target setting options • Emerging O&A mechanism options 	
13:15	Break		30 min

<p>13:45 Pneumococcal Vaccines: Considerations for use in older adults and Use in Outbreak settings – Session 9</p> <p><u>Advice to countries on use of pneumococcal vaccines in national programmes to vaccinate older adults.</u></p> <p>Introduction to session, background, and key questions. A. POLLARD. SAGE Member. 5 min.</p> <p>Summary overview of evidence. A. POLLARD. SAGE Member. 20 min.</p> <p>Proposals from the SAGE Ad-hoc Working Group Recommendations. A. POLLARD. SAGE Member. 5 min.</p> <p>Discussion: 30 min.</p> <p><u>Pneumococcal Outbreaks and Strategies for prevention and response</u></p> <p>Summary of Evidence – M. KNOLL J. Hopkins U. 10 min.</p> <p>Conclusions and Recommendations. A. POLLARD. SAGE Member. 5 min.</p> <p>Discussion: 15 min.</p>	<p>FOR DECISION</p> <p>Present SAGE with a review of pneumococcal disease in older adults (i.e., over 50 years); pneumococcal vaccine efficacy, effectiveness, and safety in older adults; herd effects due to childhood pneumococcal vaccination programmes; and implementation experience of adult pneumococcal vaccination programmes, including coverage, feasibility, and cost.</p> <p>SAGE is requested to address the following question:</p> <p>From a public health perspective, what key aspects should be considered by a country when determining whether to include adult pneumococcal vaccination in its national immunization programme?</p> <p>SAGE is asked to answer the following question:</p> <p>Is there evidence to support use of pneumococcal conjugate vaccines to prevent or mitigate outbreaks of pneumococcus?</p>	1h 30min
<p>15:15 Vaccine Innovation Prioritization Strategy (VIPS) - Session 10</p> <p>The Vaccine Innovation Prioritization Strategy: Process, outcomes and next steps. M. MENOZZI-ARNAUD (Gavi) and B. GIERSING (WHO). 20 min.</p> <p>Perspective from the VIPS Alliance Steering Committee chair. J ABRAMSON. 5 min.</p> <p>Discussion. 20 min.</p>	<p>FOR DISCUSSION</p> <p>Share with SAGE the process and outcomes of VIPS with a decision to prioritise 3 innovations / approaches: i) microarray patches, ii) heat stable and Controlled Temperature Chain qualified vaccines, iii) barcodes on primary packaging, for which the VIPS Alliance will further collaborate to advance development, policy and access.</p> <p>Seek endorsement from SAGE on:</p> <ul style="list-style-type: none"> - Innovative vaccine delivery technologies are needed to address immunisation barriers and achieve immunisation coverage and equity goals, including reaching zero-dose children and missed communities. - VIPS must now engage with regional immunisation, regulatory and policy-making fora to ensure validation of the perceived benefits and feasibility of the priority innovations and support to accelerate availability and access. -The VIPS Alliance has identified the key, high level workstreams that will advance vaccine product innovation in a measurable way. 	45 min
<p>16:00 End of the Plenary Meeting</p>		

Thursday, 08 October 2020

<p>12:00 Closed SAGE meeting</p>	<p>Recap of day 3. Other important discussion items.</p>	2h
---	--	----

14 September 2020

14:00 End of the meeting